Under the project, the diagnostic efficacy of rWGS will be evaluated in the institution's neonatal and pediatric intensive care units, according to the company. At least 100 critically ill children with suspected genetic disorders will be tested, as well as their parents when possible.

Illumina said that the study results will be used to challenge the existing inclusion and exclusion criteria for rWGS in intensive care settings, as well as to help establish appropriate evidence for earlier use of the test in the German healthcare system. Furthermore, researchers will also review changes in patient care and management to determine the clinical utility of rWGS, according to the company.

Finally, the test's financial impact will be analyzed by comparing the costs of rWGS with the existing diagnostic pathway for a critically ill child with a suspected genetic disorder, according to Illumina.

Illumina expands access to genomics in Latin America
Illumina has launched a new state-of-the-art facility in São Paulo, Brazil, that will expand global access to genomics in Latin America. The 11,000-sq-ft...

Illumina Accelerator invests in 7 genomics startups
Illumina has invested in seven new genomics companies to join the fourth global funding cycle of Illumina Accelerator San Francisco Bay Area and Cambridge,...

Illumina for Startups pushes boundaries of genomics by supporting early-stage companies
Most scientists are familiar with the genomics giant Illumina, which is known for its DNA sequencing technologies. However, Illumina has an accelerator...

Illumina Accelerator invests in 9 genomics startups
Illumina picked nine genomics companies to join the second global funding cycle of the Illumina Accelerator in the U.S. and U.K.

Illumina launches genomics incubator in China
Illumina has partnered with investment firm Sequoia Capital China to launch a new collaboration designed to create an incubator for startup companies...